Tudorza Pressair

FDA approves Tudorza Pressair for COPD

FDA approves Tudorza Pressair for COPD

The Food and Drug Administration recently approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.